SCHEMBL4094967

SCHEMBL4094967

CCOC(=O)N1CCN(c2nc(C3CCCCC3)nc3ccc(Cl)cc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDE P14735 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
GLA P06280 1/20 0.48
NTSR1 P30989 7/20 0.48
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
TSHR P16473 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096410 0.88 NTSR1 (0.59) IDEALDH1A1HPGDLMNAKDM4E
SCHEMBL4095281 0.87 NTSR1 (0.49) ALDH1A1NTSR1MAPT
SCHEMBL4095812 0.81 HRH4 (0.57) ALDH1A1KDM4ECASP1CASP7NTSR1
SCHEMBL4095784 0.81 NTSR1 (0.50) ALDH1A1NTSR1MAPT
SCHEMBL4097528 0.80 MEN1 (0.54) IDEALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4789131 0.79 NTSR1 (0.41) ALDH1A1NTSR1KMT2AMAPT
SCHEMBL4754337 0.78 NTSR1 (0.43) ALDH1A1LMNAKDM4ENTSR1MAPT
SCHEMBL4091440 0.77 KMT2A (0.55) IDEALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4085181 0.76 MEN1 (0.49) IDEALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4084978 0.76 MAPT (0.57) IDEALDH1A1HPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 IDE 4490/4885ALDH1A1 4857/4885HPGD 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.